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Abstract
Introduction: This study examines patient reported outcome measures of women undergoing hyperbaric oxygen
treatment (HBOT) after breast-conserving therapy.
Method: Included were 57 women treated with HBOT for late radiation-induced tissue toxicity (LRITT) referred in
the period January 2014-December 2015. HBOT consisted of (on average) 47 sessions. In total, 80 min of 100 % O2
was administered under increased pressure of 2.4 ATA. Quality of life was assessed before and after treatment using
the European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR23, and a NRS pain score.
Results: Fifty-seven women were available for evaluation before and after treatment. Before HBOT, patients had severe
complaints of pain in the arm/shoulder (46 %), swollen arm/hand (14 %), difficulty to raise arm or move it sideways
(45 %), pain in the area of the affected breast (67 %), swollen area of the affected breast (45 %), oversensitivity of the
affected breast (54 %), and skin problems on/in the area of the affected breast (32 %); post HBOT, severe complaints
were still experienced in 17, 7, 22, 15, 13, 15, and 11 % of the women, respectively. Differences were all significant.
The NRS pain score improved at least 1 point (range 0–10) in 81 % of the patients (p < 0.05).
Conclusion: In these breast cancer patients treated with HBOT for LRITT, the patient-reported outcomes were
positive and improvements were observed. HBOT was a well-tolerated treatment for LRITT and its side-effects
were both minimal and reversible.
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Introduction
In the Netherlands, around 14,000 women are diagnosed
each year with invasive breast cancer; in addition about
1,900 women are diagnosed with a ductal carcinoma in
situ [www.oncoline.nl]. According to the GLOBOCAN
series of the International Agency for Research on Cancer,
one of the most commonly diagnosed cancers worldwide
is breast cancer (1.67 million) [1]. Among women in the
Netherlands, the cumulative lifetime breast cancer risk is
12–13 % [www.oncoline.nl]. Early detection (particularly
via national breast cancer screening and improved
systemic therapy) is the main factor to improve breast
cancer prognosis [www.oncoline.nl]. In ≥ 60 % of pa-
tients, breast-conserving surgery is applied followed by
radiotherapy. A boost dose is added in patients with a
high risk of developing a true local recurrence.
When radiation is used to treat cancer it also (partly)
affects a variety of critical surrounding normal tissues
which can become hypocellular, hypovascular and
hypoxic, frequently referred to as ‘3 H tissue’ [2]. The
hypoxic status of tissues can be counteracted to some
extent by oxygenation of normal cells with hyperbaric
oxygen therapy (HBOT). The effects of hyperbaric
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oxygen can be summarized as follows: short-term effects
include reduction of edema and phagocytosis activation,
and anti-inflammatory effects. Long-term effects include
neovascularization, osteoneogenesis, and stimulation of
collagen formation by fibroblasts [3]. HBOT has shown
beneficial effects in hypoxic diabetic ulcers that result in
severe wound-healing problems and osteoradionecrosis
[4], and is frequently used for necrotic soft tissues and
bone that fails to heal. HBOT also induces significant
angiogenesis, which in one study was measurable after
eight HBOT sessions [5]. In addition, a significant in-
crease in mobilization of stem cells from the bone mar-
row occurs when HBOT is applied [6, 7], with wound
healing and recovery of normal-tissue radiation injury as
the end result [8–10].
In 25–33 %, breast cancer patients experiencing pain,
fatigue, sexual problems, anxiety, and depression [11–13].
Fatigue, worsened physical functioning, disturbed body
image and lower quality of life scores are the most
frequently reported complaints after radiotherapy and
chemotherapy [14]. Late radiation-induced tissue
toxicity (LRITT) has consequences for aftercare: for
example, radiofibrosis influences arm movement and
increases the risk of lymphedema [15]. It is also re-
ported from the EORTC 22881–10882 trial that the
10-year risk of developing moderate or severe fibrosis
is 26.2 % if a radiation boost is administered (16 Gy)
compared to 12.6 % in the no-boost arm [15]. Other
effects of LRITT include impaired cosmetic results,
fibrosis of the breast, and thoracic wall pain. Fibrosis
of the irradiated breast was shown to increase for up
to 9 years after treatment [16]. Radiation-induced thor-
acic wall pain occurs in 9.5–14.9 % of patients at 3-
year follow-up [17]. Administering a boost dose further
increases the negative impact on both health-related
quality of life and cosmetic outcome [17]. In the Dutch
Guideline for Breast Cancer (issued in 2002; revised in
2008 and 2012) HBOT is not yet mentioned due to
lack of evidence regarding its efficacy in the case of
LRITT [www.oncoline.nl].
More than 100 internationally recognized specialist
breast cancer researchers, clinicians and healthcare
professionals addressed nine thematic areas in summary
papers and concluded that there is a need to incorporate
standardized patient-reported outcome measures (PROMs)
both in clinical trials and in everyday clinical practice [18].
Deterioration in the quality of life of women treated for
breast cancer has a considerable and long-term impact
on their everyday functioning [19]. To our knowledge no
data are available regarding PROMs in patients referred
for HBOT due to LRITT. Therefore, this study aimed to
use PROMs before and after HBOT to examine whether
HBOT can significantly reduce LRITT after breast-
conserving therapy.
Methods
All patients referred to our center (January 2014 through
December 2015) for HBOT due to LRITT were asked to
participate in this study. Participation consisted of suc-
cessively completing the following PROMs before and
after HBOT: 1) the European Organization for Research
and Treatment of Cancer (EORTC) core Quality of Life
Questionnaire (QLQ), i.e. the QLQ-C30, 2) the disease-
specific EORTC QLQ-BR23, and 3) the EQ-5D health
status questionnaire and a numeric rating scale (NRS)
pain score.
Ethics approval and consent to participate
According to the AMC Ethics Committee, no ethical
approval or patient consent were needed since late ra-
diation toxicity is a treatment indication for hyperbaric
oxygen treatment and the questionnaires were distrib-
uted as part of the regular treatment evaluation.
Hyperbaric oxygen therapy
HBOT treatment consisted of (on average) 47 sessions
(1 session a day/5 days a week) in a multiplace (20-person)
hyperbaric chamber. In total 80 min of 100 % oxygen was
administered to patients under increased pressure of 2.4
atmospheres absolute (ATA) during a 110-min hyperbaric
session. At this pressure, 100 % oxygen was delivered via
an oronasal mask in four episodes of 20 min, each inter-
rupted by 5 min of air breathing. During pressure changes,
great care was taken to avoid barotraumas, particularly of
the middle ear, which is the most common side-effect of a
hyperbaric treatment [20].
Quality of life questionnaires
Questionnaires were given at the start of the treatment
and in the last week of HBOT. The core questionnaire
(QLQ-C30) applies to all patients with cancer, and the
disease-specific questionnaire (QLQ-BR23) is designed
specifically for patients with breast cancer. The QLQ-
C30 includes 30 questions comprising both multi-item
scales and single-item measures. The QLQ-BR23 com-
prises 23 questions incorporating items covering symp-
toms and side-effects related to different treatment
modalities, body image, sexuality, and future perspective.
For these items and scales, higher scores indicate more
problems. For the QLQ-BR23, scores were dichotomized
into no problems (score 1–2) and severe problems
(score 3–4). In addition, a NRS (range 0–10) was used
to rate pain before and after HBOT. Regarding the EQ-
5D, a positive difference of at least 1 point has been
noted as improvement.
Statistical analysis
Analyses were performed in MS Excel and R (http://
www.R-project.org). The cumulative linked mixed model
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was used to compare scores before and after HBOT for
the QLQ-BR23, the EQ-5D questionnaires and the NRS
pain score. A two-sided p-value of 5 % was considered
to be statistically significant.
Results
A total of 57 female patients with pre- and post HBOT
questionnaires (the QLQ-C30 and the QLQ-BR23) were
available for evaluation. Table 1 presents the baseline
characteristics of the study population.
Before HBOT, 46, 14, 45, 67, 45, 54 and 32 % of the
patients had severe complaints of pain in the arm/shoulder,
swollen arm/hand, difficulty to raise the arm or to move it
sideways, pain in the area of affected breast, swollen area
of affected breast, oversensitivity of the affected breast, and
skin problems on or in the area of the affected breast, re-
spectively. Post HBOT, the percentages of patients with
these severe complaints had decreased (Table 2). Table 2
also shows the results of the cumulative linked mixed
model analysis for the relevant questions regarding the
side-effects of breast cancer irradiation. All cumulative
linked mixed model coefficients were positive and
significant.
For the EQ-5D, 46 completed questionnaires could be
analyzed. Mobility, self-care, activity, pain, and anxiety
improved by 88, 50, 50, 75, and 80 %, respectively. The
total EQ-5D score improved in 71 % (median 9.5 to 7.7
points) of the patients while the NRS pain score (median
5 to 2) improved in 81 % of the patients (<0.05).
The side-effects of HBOT were minimal, i.e. 8/57 pa-
tients had reversible myopia and 8/57 had reversible
tiredness.
Discussion
This is the first study to show that breast cancer patients
treated with HBOT due to LRITT significantly improved
on all domains of the QLQ-BR23. In addition, the NRS
score improved in the majority of these patients.
LRITT is observed in ≤ 30 % of patients treated for
breast cancer [15, 21, 22]. This rate is much higher than
the rate of referrals for treatment of these side-effects
with hyperbaric oxygen in the clinic. Serious side-effects
observed after breast irradiation include impaired cos-
metic results, fibrosis of the breast, and thoracic wall
pain; unfortunately, for the present study population no
data are available on the cosmetic results. Collette et al.
published a breast fibrosis nomogram showing a strong
association between radiotherapy dose and fibrosis, with
large boost volumes as a prognostic factor on univariate
analysis only in the EORTC 22881–10882 trials [15].
Carl et al. reported on 44 patients with persisting
symptoms after breast-conservation therapy: of these,
32 women received HBOT for a median of 25 sessions
and 12 were control patients [23]. The HBOT patients
showed a significant reduction in pain, edema and ery-
thema scores using the LENT-SOMA scale (provider
reported) as compared to non-HBOT controls; in that
study, fibrosis and telangiectasia were not significantly
affected by HBOT [23]. In their study, Mukesh et al.
examined the volume effect by developing a predictive
Normal Tissue Complication Probability (NTCP) model
[5] and suggested that the maximum radiotherapy dose
is the most important parameter to influence late breast
fibrosis [24, 25]. However, the authors warned that this
may reflect limitations in the current scoring system,
that other radiotherapy-associated complications should
also be analyzed to determine the effects of dose-volume
parameters, and that PROMs should complement
clinician score-based models in the future. Therefore,
the authors conclude that inclusion of other clinical
factors is recommended for future NTCP modeling
work [24, 25].
Table 1 Characteristics of the study population (n = 57)
Age in years: mean 59
Median (range) 58 (32–78)
T Stage
Tis 2
T1 23
T2 18
T3 1
T4 1
Unknown 12
N Stage
N0 29
N1 10
N2 4
N3 1
Unknown 13
Time since radiotherapy (months)
Mean 57
Median (range) 33 (9–251)
Maximum radiotherapy dose (Gy)
Mean 53
Median (range) 56 (19–56)
Chemotherapy
Yes 29
No 27
Unknown 1
Surgery
Yes 50
No 6
Unknown 1
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Vilholm et al. defined the following risk factors for the
development of postmastectomy pain syndrome (PMPS):
having undergone breast surgery earlier (OR 8.12),
tumor located in the upper lateral quarter (OR 6.48),
young age (OR 1.04), and axillary lymph node dissection
(OR 1.99) [14]. The authors concluded that, although
advances in diagnostic and surgical procedures have re-
duced the frequency of the more invasive surgical proce-
dures, there is still a considerable risk of developing PMPS
after treatment for breast cancer, and that development of
preventive measures (as well as treatment of the syn-
drome) are highly relevant [14]. This might be a rationale
for starting a prospective study with HBOT immediately
followed by radiotherapy in a prophylactic setting.
Limitation in arm movement is another side-effect of
breast cancer treatments. Kootstra et al. reported that
axillary node dissection affects muscle strength, range of
shoulder motion and arm volume [26].
In the Cambridge Breast Intensity Modulated Radio-
therapy Trial, Barnett et al. reported patient and
treatment-related factors that influence late toxicity,
where the greatest risk factors for the development of
late toxicity 2 years after breast-conserving surgery
and adjuvant breast radiotherapy are a larger breast
volume independent of dose inhomogeneity, baseline
pre-radiotherapy surgical cosmesis, postoperative in-
fection, and smoking [27]. Previous factors seem to be
more important than dose inhomogeneity and the
addition of boost radiotherapy at 2 years after the
completion of radiotherapy. Unfortunately data on
these factors were not available for our patients, which
is a limitation of the present study. Mukesh et al. re-
ported that skin telangiectasia is associated with older
age, postoperative breast infection and tumor bed
boost, and increasing breast volume [28].
No prospectively randomized trials are available on
the efficacy of HBOT in breast cancer patients. In a
Cochrane review, Bennett et al. concluded that there is
some evidence that HBOT improves outcomes in late
radiation induced toxicity [4]. In their large double-blind
randomized study, Clarke et al. showed the substantial
benefit of HBOT on quality of life in chronic refractory
radiation induced proctitis [29]. Glover et al. reported in
a clinical trial of 46 participants in the hyperbaric oxy-
gen group and 23 participants in the control group, no
significant differences in the change of IBDQ bowel
component score. From the 29 participants in the hyper-
baric oxygen group and 11 participants in the sham
group with rectal bleeding at baseline, also no significant
differences in the change of IBDQ rectal bleeding score
were seen. Several letter to the editors are published re-
garding the study setup thereafter in the journal [30].
The possible benefit of HBOT immediately after radio-
therapy to prevent/reduce late side-effects of radiation
in head and neck cancer was examined in another ran-
domized pilot study [2]; this latter study showed that pa-
tients receiving hyperbaric oxygen after radiotherapy
had better quality of life scores for swallowing, sticky
saliva, xerostomia, and pain in the mouth. Tahir et al.
presented Australia’s largest study for chronic radiation-
induced tissue injuries treated with hyperbaric oxygen,
evaluated by the Common Terminology Criteria for
Adverse Events v3.0 (CTCAE) grading system [20]. This
is a provider-reported study (whereas our study reflects
the patient’s point of view) in which the authors demon-
strate that HBOT can be effectively applied in a variety
of chronic radiation-induced tissue, including the breast.
Our HBOT protocol for LRITT of breast-conserving
therapy included (on average) 47 sessions; this number
was required for a maximum effect in reducing complaints.
Although our protocol is usually patient-tailored for a
minimum of 40 sessions, the prescribed amount of treat-
ment varies per individual patient. Future research could
examine the optimal amount of HBO treatment to reduce
problems related to LRITT. The present study demon-
strates a significant improvement in quality of life based on
PROMs after HBOT for LRITT after breast-conserving
treatment. A randomized controlled trial (including
PROMs) is recommended to provide more substantial
evidence concerning the value of HBOT in these patients.
Table 2 Scores on the EORTC BR23 Questionnaire
n Pre HBOT,
Severe
problems
Post HBOT,
Severe
problems
Improvement Mean Pre
HBOT to Post
HBOT
Cumulative linked
mixed model
(p value)
Did you have any pain in your arm or shoulder? 56 46.4 % 16.7 % 42.6 % 2.4 to1.8 1.7 (p <0.05)
Did you have a swollen arm or hand? 56 14.3 % 7.4 % 25,9 % 1.6 to 1.4 1.2 (p <0.05)
Was it difficult to raise your arm or to move it sideways? 56 44.6 % 22.2 % 42.9 % 2.4 to 1.9 2.1 (p <0.05)
Have you had any pain in the area of your affected breast? 56 66.7 % 14.5 % 63.6 % 2.8 to 2.1 2.4 (p <0.05)
Was the area of your affected breast swollen? 57 44.6 % 12.7 % 57.9 % 2.4 to 1.7 2.0 (p <0.05)
Was the area of your affected breast oversensitive? 57 54.4 % 14.5 % 54.5 % 2.7 to 2.0 1.9 (p <0.05)
Have you had skin problems on or in the area of your affected
breast (e.g., itchy, dry, flaky)?
57 32.1 % 11.3 % 41.5 % 2.0 to 1.6 1.5 (p <0.05)
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Conclusions
The use of PROMs in breast cancer patients treated with
HBOT for radiation-induced late tissue toxicity was
valuable and revealed a significant improvement in the
related complaints. The side-effects of HBOT were both
minimal and reversible.
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